Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company with over 30 years of experience in developing and commercializing products that treat central nervous system (CNS) diseases. self-described.

COM:SUPERNUS

Supernus Pharmaceuticals

Last Close

35.82

22/11 21:00

Market Cap

2.00B

Beta: -

Volume Today

190.74K

Avg: -

People Not Available